Dergiler / Sakarya University Journal of Science / 2023 / Cilt: 27 Sayı: 6

Evaluation of the Antigenotoxic Effect of Quercetin Against Antiepileptic Drug Genotoxicity by Comet Analysis

Sayfa
1185–1196
Yayın Tarihi
2023-12-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Our analysis results showed that QUE ameliorates VPA-induced genetic damage.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Valproic acid (VPA) is among the most commonly used antiepileptic drugs in childhood and adult epilepsy.
📊
Temel Bulgular & Veri:Although VPA is well tolerated, it can cause life-threatening side effects.
💡
Sonuç & Katkı:Our analysis results showed that QUE ameliorates VPA-induced genetic damage.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Valproic acid · comet assay · in vitro

Abstract

Valproic acid (VPA) is among the most commonly used antiepileptic drugs in childhood and adult epilepsy. Although VPA is well tolerated, it can cause life-threatening side effects. VPA has toxic and genotoxic effects. Antioxidants can reverse drugs' toxic and genotoxic effects. Therefore, our study aimed to evaluate the antigenotoxic protective effect of quercetin (QUE) against VPA genotoxicity by in vitro comet assay analysis method. Comet assay analysis was performed in five different groups. Group I; negative control (Sterile H2O), Group II; positive control (H2O2), Group III; VPA was applied in four different dose ranges, Group IV; QUE was applied in four different dose ranges, Group V; For the simultaneous combined administration of VPA and QUE, three different doses of VPA + four different doses of QUE were administered. Low-dose administration of QUE was more effective in ameliorating the damage caused by low-dose VPA (62.5 μg/ml) administration. It is seen that the genotoxic damage caused by the application of 125 μg/ml VPA can be eliminated by QUE at all doses. It was determined that different doses of QUE exhibited a significant antigenotoxic effect against damage caused by 125 µg/mL VPA (P<0.05). In our study, the curative effect of QUE on DNA damage was determined by in vitro comet analysis. Our analysis results showed that QUE ameliorates VPA-induced genetic damage.

🔖

Bu Makaleye Atıf Yap

CANBOLAT, F., KENANOĞLU, N. A., YÜKSEL, T. N., BERBER, A. A. (2023). Evaluation of the Antigenotoxic Effect of Quercetin Against Antiepileptic Drug Genotoxicity by Comet Analysis. Sakarya University Journal of Science, Cilt: 27 Sayı: 6, 1185–1196. https://ajindex.com/articles/1022308

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. P. Haznedar, “Çocukluk çağı epilepsilerinde levetirasetam ve valproik asit tedavisinin karaciğer fonksiyonları, plazma serbest karnitin ve lipid peroksidasyonu ile oksidatif DNA hasarı üzerine etkileri,” Çocuk Sağlığı ve Hastalıkları Anabilim Dalı Tıpta Uzmanlık Tezi, Ankara üniversitesi, 2017
  2. D. A. Colak, C. Ersöz, “Sisplatin ve valproik asitin indüklediği toksisiteye karşı kudret narının Drosophila melanogaster’in yaşama yüzdesi ve ömür uzunluğu üzerine etkisi,” Eurasian Journal of Biological and Chemical Sciences, vol.2, no.2, pp.73- 78, 2018
  3. T. Tomson, D. Battino, E. Perucca, “Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honored drug,” Lancet Neurology, vol.15, no.2, pp.210-218, 2016
  4. M. D. Sztajnkrycer, “Valproic acid toxicity: overview and management,” Journal of Toxicology: Clinical Toxicology, vol. 40, no. 6, pp.789-801, 2002
  5. I. T. Okay, C. Kısa, N. Dilbaz, “Psikiyatrik bozukluklarda valproat kullanımı”, Klinik Psikiyatri, vol. 5, 33- 41, 2002
  6. C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier, K. Egberts, M. Fric, M. Gerlach, C. Greiner, G. Grunder, E. Halen, U. Havemann-Reinecke, E. Jaquenoud Sirot, H. Kircherr, G. Laux, U.C. Lutz, T. Messer, M.J. Müller, B. Pfuhlmann, B. Rambeck, P. Riederer, B. Schoppek, J. Stingl, M. Uhr, S. Ulrich, R. Waschgler, G. Zernig, “AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011”, Pharmacopsychiatry, vol. 44, no. 06, pp.195-235, 2011
  7. F. E. Dreifuss, N. Santilli, D. H. Langer, K. P. Sweeney, K. A. Moline, K. B. Menander, “Valproic acid hepatic fatalities: a retrospective review,” Neurology, vol. 37, no. 3, pp. 379-85, 1987
  8. F. J. Romero, F. Bosch-Morell, M. J. Romero, E. J. Jareño, B. Romero, N. Marín, J. Romá, “Lipid peroxidation products and antioxidants in human disease,” Environmental Health Perspectives, vol. 106, no. 5, pp. 1229, 1998
  9. D. Coulter, “Carnitine deficiency: a possible mechanism for valproate hepatotoxicity,” The Lancet, vol. 323, no. 8378, pp.689, 1984
  10. T. Devasagayam, J. Tilak, K. Boloor, K. S. Sane, S. S. Ghaskadbi, R. Lele, “Free radicals and antioxidants in human health: current status and future prospects,” Journal of the Association of Physicians of India, vol. 52, no.10, pp.794-804, 2004
  11. A. S. Yalçın, A. M. Yılmaz, E. M. Altundag, S. Koçtürk, “Kurkumin, kuersetin ve çay kateşinlerinin antikanser etkileri,” Marmara Pharmaceutical Journal, vol. 2